2025³â Ç÷¹³Ê¸® ¼¼¼Ç(±âÁ¶ °¿¬ ÇÁ·Î±×·¥)
Àü ¼¼°èÀÇ µ¿·áµé°ú ÇÔ²² Discovery on Target Ç÷¹³Ê¸® ¼¼¼Ç(±âÁ¶ °¿¬ ÇÁ·Î±×·¥)¿¡ Âü°¡Çϼ¼¿ä. 9¿ù 24ÀÏ(¼ö)¿¡ À̺¥Æ® Àü¹Ý°ú ÈĹÝÀ» ¿¬°áÇÏ´Â Ç÷¹³Ê¸® ¼¼¼ÇÀÇ ±âÁ¶ °¿¬ÀÌ ÁøÇàµË´Ï´Ù. Drug Discovery Àü¹®°¡ Ä¿¹Â´ÏƼ Àüü°¡ ÇÑÀÚ¸®¿¡ ¸ð¿© ¾÷°è Àú¸íÀλç·ÎºÎÅÍ Àüü»ó, Çõ½ÅÀûÀÎ ±â¼ú, »ý°¢À» ÀÚ±ØÇÏ´Â Æ®·»µå¿¡ ´ëÇØ ¹è¿ï ¼ö ÀÖ´Â À¯ÀÏÇÑ ±âȸÀÔ´Ï´Ù. 9¿ù 25ÀÏ(¸ñ)ÀÇ Ç÷¹³Ê¸® º¥Ã³Ä³ÇÇÅÐ ÆÐ³Î¿¡¼´Â º¥Ã³Ä³ÇÇÅп¡ ÀÇÇÑ ÃֽŠÀλçÀÌÆ® ¹× µ¿Çâ¿¡ ´ëÇØ µéÀ» ¼ö ÀÖ½À´Ï´Ù.
WEDNESDAY, SEPTEMBER 24
PLENARY KEYNOTE PRESENTATION
Gregory L Verdine, PhD, Co Founder & President & CEO & CTO, LifeMine Therapeutics
THURSDAY, SEPTEMBER 25
Insights from Venture Capitalists: Trends in Drug Discovery
Panel Moderator: Daniel A. Erlanson, PhD, Chief Innovation Officer, Frontier Medicines Corporation
* ÁÖÃÖÃø »çÁ¤¿¡ µû¶ó »çÀü ¿¹°í¾øÀÌ ÇÁ·Î±×·¥ÀÌ º¯°æµÉ ¼ö ÀÖ½À´Ï´Ù.